ELEckhard Lammert

Eckhard Lammert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eckhard Lammert has a total of 232 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel Eberhard

    Heinrich Heine University Düsseldorf, Faculty of Mathematics and Natural Sciences, Institute of Metabolic Physiology, Düsseldorf, Germany

    9 shared publications
  • Barbara Bartosinska

    5 shared publications
  • Daniel Eberhard

    Heinrich Heine University Düsseldorf

    5 shared publications
  • Jessica Mrugala

    5 shared publications
  • Alena Welters

    Institute of Metabolic Physiology, Heinrich Heine University, 40225 Düsseldorf, Germany; Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, 40225 Düsseldorf, Germany

    4 shared publications
  • Andrea Köster

    Heinrich Heine University Düsseldorf, Faculty of Mathematics and Natural Sciences, Institute of Metabolic Physiology, Düsseldorf, Germany

    4 shared publications

Latest Publications

  • Open Access

    Enhancing pancreatic islet cell survival via NMDAR antagonist-driven ROR1 activation as revealed by phosphoproteomics

    by Philip Kirschner, Celine Weippert, Sonja Hartwig, Bengt-Frederik Belgardt, Stefan Lehr, Daniel Eberhard, Hadi Al-Hasani, Eckhard Lammert

    NMDA receptors (NMDARs) control function and survival not only of neurons, but also of insulin-producing pancreatic beta cells. Since insufficient insulin secretion and beta cell death are key events during diabetes development, targeting NMDARs offers a therapeutic approach. Specifically, the NMDAR antagonist dextrorphan (DXO) increases glucose-stimulated insulin secretion in clinical trials. Furthermore, treatment with DXO or optimized DXO derivatives prevents pancreatic islet cell death upon diabetogenic insults. Nonetheless, the signaling pathways induced by NMDAR inhibition are poorly understood. Here, we use complementary approaches, phosphoproteomics and tyrosine kinase profiling, to demonstrate that DXO and its derivatives rapidly regulate multiple intracellular signaling clusters, including mTOR and ERK signaling, in pancreatic islets. Notably, mTOR inhibition, but not ERK inhibition, is sufficient to negate DXO's protective effects. Further, we show that activation of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) is a universal event upon NMDAR inhibition in islets. Simultaneous knockdown of Ror1/ROR1 and its paralogue Ror2/ROR2 compromises the viability of both mouse and human islets, highlighting the ROR1/2 signaling axis as a promising avenue for enhancing beta cell survival.

  • Open Access

    Endothelial nitric oxide signaling in cellular and systemic metabolism

    by Mauro Siragusa, Luke S. Dunaway, Eckhard Lammert, Ingrid Fleming, Brant E. Isakson, Miriam M. Cortese-Krott

  • Open Access

    Obesity drives depot-specific vascular remodeling in male white adipose tissue

    by Sana S. Hasan, David John, Martina Rudnicki, Ibrahim AlZaim, Daniel Eberhard, Iris Moll, Jacqueline Taylor, Christian Klein, Maximilian von Heesen, Lena-Christin Conradi, et al.

    Obesity-driven pathological expansion of white adipose tissue (WAT) is a key driver of endothelial dysfunction. However, early vascular alterations associated with over-nutrition also serve to exacerbate WAT dysfunction. Here, we conduct a single-cell transcriptomic analysis of WAT endothelium to delineate endothelial heterogeneity and elucidate vascular alterations and its consequence in a male murine model of obesity. We demarcate depot-specific differences in subcutaneous (sWAT) and visceral WAT (vWAT) endothelium through in sillico analysis and further corroboration of our findings. Moreover, we identify a sWAT-specific fenestrated endothelial cell (EC) subtype, which declines in obese conditions. Utilizing systemic anti-VEGFA blockade and genetic Vegfa manipulation, we demonstrate that VEGFA is necessary for maintaining fenestration in sWAT. Additionally, we detect this fenestrated EC subtype in male human WAT, which undergoes reduction in individuals with obesity. Collectively, this atlas serves as a valuable tool for future studies to decipher the functional significance of different WAT EC subtypes.


  • Open Access

    The Alzheimer’s disease–linked protease BACE2 cleaves VEGFR3 and modulates its signaling

    by Andree Schmidt, Brian Hrupka, Frauke van Bebber, Sanjay Sunil Kumar, Xiao Feng, Sarah K. Tschirner, Marlene Aßfalg, Stephan A. Müller, Laura Sophie Hilger, Laura I. Hofmann, et al.

    The β-secretase β-site APP cleaving enzyme (BACE1) is a central drug target for Alzheimer’s disease. Clinically tested, BACE1-directed inhibitors also block the homologous protease BACE2. Yet little is known about physiological BACE2 substrates and functions in vivo. Here, we identify BACE2 as the protease shedding the lymphangiogenic vascular endothelial growth factor receptor 3 (VEGFR3). Inactivation of BACE2, but not BACE1, inhibited shedding of VEGFR3 from primary human lymphatic endothelial cells (LECs) and reduced release of the shed, soluble VEGFR3 (sVEGFR3) ectodomain into the blood of mice, nonhuman primates, and humans. Functionally, BACE2 inactivation increased full-length VEGFR3 and enhanced VEGFR3 signaling in LECs and also in vivo in zebrafish, where enhanced migration of LECs was observed. Thus, this study identifies BACE2 as a modulator of lymphangiogenic VEGFR3 signaling and demonstrates the utility of sVEGFR3 as a pharmacodynamic plasma marker for BACE2 activity in vivo, a prerequisite for developing BACE1-selective inhibitors for safer prevention of Alzheimer’s disease.


  • Open Access

    Semaphorin-3A regulates liver sinusoidal endothelial cell porosity and promotes hepatic steatosis

    by Daniel Eberhard, Sydney Balkenhol, Andrea Köster, Paula Follert, Eric Upschulte, Philipp Ostermann, Philip Kirschner, Celina Uhlemeyer, Iannis Charnay, Christina Preuss, et al.

    Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, increases worldwide and associates with type 2 diabetes and other cardiometabolic diseases. Here we demonstrate that Sema3a is elevated in liver sinusoidal endothelial cells of animal models for obesity, type 2 diabetes and MASLD. In primary human liver sinusoidal endothelial cells, saturated fatty acids induce expression of SEMA3A, and loss of a single allele is sufficient to reduce hepatic fat content in diet-induced obese mice. We show that semaphorin-3A regulates the number of fenestrae through a signaling cascade that involves neuropilin-1 and phosphorylation of cofilin-1 by LIM domain kinase 1. Finally, inducible vascular deletion of Sema3a in adult diet-induced obese mice reduces hepatic fat content and elevates very low-density lipoprotein secretion. Thus, we identified a molecular pathway linking hyperlipidemia to microvascular defenestration and early development of MASLD.


  • Open Access

    Identification of myeloid-derived growth factor as a mechanically-induced, growth-promoting angiocrine signal for human hepatocytes

    by Linda Große-Segerath, Paula Follert, Kristina Behnke, Julia Ettich, Tobias Buschmann, Philip Kirschner, Sonja Hartwig, Stefan Lehr, Mortimer Korf-Klingebiel, Daniel Eberhard, et al.

    Recently, we have shown that after partial hepatectomy (PHx), an increased hepatic blood flow initiates liver growth in mice by vasodilation and mechanically-triggered release of angiocrine signals. Here, we use mass spectrometry to identify a mechanically-induced angiocrine signal in human hepatic endothelial cells, that is, myeloid-derived growth factor (MYDGF). We show that it induces proliferation and promotes survival of primary human hepatocytes derived from different donors in two-dimensional cell culture, via activation of mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3). MYDGF also enhances proliferation of human hepatocytes in three-dimensional organoids. In vivo, genetic deletion of MYDGF decreases hepatocyte proliferation in the regenerating mouse liver after PHx; conversely, adeno-associated viral delivery of MYDGF increases hepatocyte proliferation and MAPK signaling after PHx. We conclude that MYDGF represents a mechanically-induced angiocrine signal and that it triggers growth of, and provides protection to, primary mouse and human hepatocytes.


  • Open Access

    Protection of pancreatic islets from oxidative cell death by a peripherally-active morphinan with increased drug safety

    by Okka Scholz, Elena Huß, Silke Otter, Diran Herebian, Anna Hamacher, Laura Mariana Levy, Stanimira Hristeva, Miguel Sanz, Haresh Ajani, Alfredo Rodriguez Puentes, et al.


  • Open Access

    Pancreatic islet protection at the expense of secretory function involves serine-linked mitochondrial one-carbon metabolism

    by Angela Pelligra, Jessica Mrugala, Kerstin Griess, Philip Kirschner, Oliver Nortmann, Barbara Bartosinska, Andrea Köster, Natalia I. Krupenko, Dominik Gebel, Philipp Westhoff, et al.


  • Open Access

    Pancreatic islet protection at the expense of secretory function involves serine-linked mitochondrial one-carbon metabolism

    by Angela Pelligra, Jessica Mrugala, Kerstin Griess, Philip Kirschner, Oliver Nortmann, Barbara Bartosinska, Andrea Köster, Natalia I. Krupenko, Dominik Gebel, Philipp Westhoff, et al.


  • Pancreatic islet protection at the expense of secretory function associates with serine-linked one-carbon metabolism

    by Angela Pelligra, Jessica Mrugala, Kerstin Griess, Oliver Nortmann, Barbara Bartosinska, Andrea Köster, Natalia Krupenko, Dominik Gebel, Philipp Westhoff, Bodo Steckel, et al.

    Type 2 diabetes (T2D) is the most common metabolic disease worldwide and is characterized by insulin hypersecretion, followed by reduced glucose-stimulated insulin secretion (GSIS). Even though much has been discovered about insulin producing beta cell physiology, the molecular mechanisms behind beta cell decay in T2D are still unknown and no anti-diabetic drug is available to fully halt or reverse this process. Here, we show that short-term in vitro stimulation of mouse pancreatic islets with insulin secretagogue dextrorphan (DXO) enhances GSIS, but does not protect islets from cell death. In contrast, long-term insulin hypersecretion induced by DXO reduces GSIS, but protects islets from cell death. Bulk RNA sequencing of islets reveals increased expression of genes encoding enzymes of the serine-linked mitochondrial one-carbon metabolism (OCM) after long-term, but not short-term stimulation. In long-term stimulated islets, more glucose was metabolized to serine than citrate, and mitochondrial concentrations of ATP decreased, despite unaltered oxygen consumption, while NAPDH increased. Activating transcription factor-4 (Atf4) is shown to be required and sufficient to activate serine-linked mitochondrial OCM genes in islets, and gain- and loss-of-function experiments revealed that Atf4 reduces GSIS and is necessary, but not solely sufficient for full DXO-mediated islet cell protection. Furthermore, we show that de novo serine synthesis enzyme phosphoglycerate dehydrogenase (Phgdh) and enzymes of the mitochondrial OCM, such as serine hydroxymethyltransferase 2 (Shmt2) and methylenetetrahydrofolate dehydrogenase 2 (Mthfd2), reduce GSIS and regulate islet cell death. In summation, we identified a reversible metabolic pathway associated with islet cell protection at expense of secretory function. Article published online: 02 May 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany